Gan & Lee developed the first Chinese domestic insulin analog, and as of Q4 2024 has six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin), fast-acting lispro injection (Prandilin), fast-acting aspart injection (Rapilin), mixed protamine zinc lispro injection (Prandilin25), aspart 30 injection (Rapilin30), and one human insulin injection - mixed protamine human insulin injection (Similin30). The company has two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine).